CD274 and hepatocellular carcinoma: In a phase II trial involving patients with unresectable HCC, the combination of tremelimumab (anti-CTLA-4 antibody) plus durvalumab (a PD-L1 inhibitor) demonstrated promising clinical activity and safety [43].